JP Morgan Chase
ARKG icon

JP Morgan Chase’s ARK Genomic Revolution ETF ARKG Stock Holding History

JP Morgan Chase’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$315M Buy
7,443,296
+212,487
+3% +$6.77M 0.02% 599
2026
Q1 		$179M Buy
7,230,809
+2,081,355
+40% +$61M 0.01% 733
2025
Q4 		$149M Buy
5,149,454
+1,205,541
+31% +$36.2M 0.01% 779
2025
Q3 		$110M Sell
3,943,913
-410,039
-9% -$10.4M 0.01% 947
2025
Q2 		$106M Buy
4,353,952
+920,430
+27% +$20.2M 0.01% 910
2025
Q1 		$71.3M Buy
3,433,522
+641,951
+23% +$16.1M 0.01% 1105
2024
Q4 		$65.7M Sell
2,791,571
-163,708
-6% -$4.03M ﹤0.01% 1152
2024
Q3 		$75.7M Buy
2,955,279
+699,901
+31% +$17.8M 0.01% 1089
2024
Q2 		$53M Buy
2,255,378
+1,124,827
+99% +$28.4M ﹤0.01% 1217
2024
Q1 		$32.5M Buy
1,130,551
+797,006
+239% +$24M ﹤0.01% 1556
2023
Q4 		$10.9M Buy
333,545
+104,276
+45% +$2.84M ﹤0.01% 2373
2023
Q3 		$6.39M Buy
229,269
+35,724
+18% +$1.17M ﹤0.01% 2651
2023
Q2 		$6.6M Buy
193,545
+8,712
+5% +$274K ﹤0.01% 2649
2023
Q1 		$5.56M Buy
184,833
+168,398
+1,025% +$5.22M ﹤0.01% 2733
2022
Q4 		$464K Sell
16,435
-1,452
-8% -$46.1K ﹤0.01% 4573
2022
Q3 		$588K Buy
17,887
+2,633
+17% +$96.7K ﹤0.01% 4352
2022
Q2 		$480K Sell
15,254
-220,225
-94% -$7.7M ﹤0.01% 4594
2022
Q1 		$10.8M Sell
235,479
-219,773
-48% -$10.5M ﹤0.01% 2292
2021
Q4 		$27.9M Buy
455,252
+75,140
+20% +$5.19M ﹤0.01% 1543
2021
Q3 		$28.4M Buy
380,112
+41,365
+12% +$3.47M ﹤0.01% 1509
2021
Q2 		$31.3M Buy
338,747
+20,895
+7% +$1.78M ﹤0.01% 1484
2021
Q1 		$28.2M Buy
317,852
+224,948
+242% +$22.3M ﹤0.01% 1476
2020
Q4 		$8.66M Buy
92,904
+84,565
+1,014% +$6.74M ﹤0.01% 2325
2020
Q3 		$535K Sell
8,339
-5,269
-39% -$309K ﹤0.01% 3949
2020
Q2 		$709K Buy
13,608
+2,947
+28% +$126K ﹤0.01% 3699
2020
Q1 		$334K Buy
10,661
+2,438
+30% +$81.5K ﹤0.01% 4037
2019
Q4 		$276K Buy
+8,223
New +$261K ﹤0.01% 4548

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase's ARKG Position: Q2 2026 in Review

JP Morgan Chase increased its ARK Genomic Revolution ETF (ARKG) stake by 2.9% in Q2 2026, buying an estimated $6.77M and bringing the position to 7,443,296 shares worth $315M. The position accounts for 0.02% of the portfolio, ranked #599.

JP Morgan Chase first reported a position in ARKG in Q4 2019 and has held it in 27 quarters since. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • JP Morgan Chase held 7,443,296 shares of ARK Genomic Revolution ETF worth $315M as of Q2 2026.
  • JP Morgan Chase bought 212,487 ARK Genomic Revolution ETF shares in Q2 2026, an estimated $6.77M.
  • ARK Genomic Revolution ETF made up 0.02% of JP Morgan Chase's portfolio in Q2 2026, its #599 holding.
  • JP Morgan Chase first reported a position in ARK Genomic Revolution ETF in Q4 2019 and has held it in 27 quarters since.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.